talazoparib tosylate · Pfizer · NDA 211651, 217439

Talzenna

Earliest generic entry, as listed · earliest of 6 marketed strengths
16 Oct 2032

Blocked by patent: US 8012976.

Listed patents · 6 unexpired

PatentClaimsExpires
US 8012976drug substance, drug product · sets the listed date16 Oct 2032
US 10189837drug substance, drug product20 Oct 2031
US 8735392drug substance, drug product20 Oct 2031
US 10780088use U-365127 Jul 2029
US 8420650drug substance, drug product27 Jul 2029
US 9820985use U-243727 Jul 2029

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 12

NDA · productFormStrengthListed expiry
211651 · 001 · RLD · discontinuedcapsule, oralEQ 0.25MG BASE16 Oct 2032
211651 · 002 · RLD · discontinuedcapsule, oralEQ 1MG BASE16 Oct 2032
211651 · 003 · RLD · discontinuedcapsule, oralEQ 0.5MG BASE16 Oct 2032
211651 · 004 · RLD · discontinuedcapsule, oralEQ 0.75MG BASE16 Oct 2032
211651 · 005 · RLD · discontinuedcapsule, oralEQ 0.1MG BASE16 Oct 2032
211651 · 006 · RLD · discontinuedcapsule, oralEQ 0.35MG BASE16 Oct 2032
217439 · 001 · RLDcapsule, oralEQ 0.1MG BASE16 Oct 2032
217439 · 002 · RLDcapsule, oralEQ 0.25MG BASE16 Oct 2032
217439 · 003 · RLDcapsule, oralEQ 0.35MG BASE16 Oct 2032
217439 · 004 · RLDcapsule, oralEQ 0.5MG BASE16 Oct 2032
217439 · 005 · RLDcapsule, oralEQ 0.75MG BASE16 Oct 2032
217439 · 006 · RLDcapsule, oralEQ 1MG BASE16 Oct 2032
Expired or delisted (1)
  • I-920 · 20 Jun 2026